CancerReport 2021

CANCER REPORT 2021

COLORECTAL

Table 5.3 Age and gender of colorectal cancer. 65.3 (12.9)
66.0 (23:104)
Special Notes
Age 0.0%
Mean and standard deviation age at diagnosis (years)
241 (53.1%)
Median and range age at diagnosis 213 (46.9%)
% of the patient is lower than 15 year of age at diagnosis
Gender 1.13:1
Male
Female Total
Sex ratio (male: female) N%
454 100.0
Table 5.4 Most valid method of diagnosis for colorectal cancer. 454 100.0

Basis of diagnosis Male % Female
Histology of primary N 100.0 N%
241 213 100.0

Total 241 100.0 213 100.0

90

80

70

60

50

40

30

20

10

0
20+ 30+ 40+ 50+ 60+ 70+ 80+

Male 1 5 18 53 78 61 25

Female 0 8 18 41 57 54 35

Figure 5.4 Age at diagnosis of colorectal cancer, 2021, by sex.

44

CANCER REPORT 2021

Stage I, 5.9%
Unknown, 8.2%

Stage II, 22.7%

Stage IV, 33.3%

Stage III, 30.0%

Figure 5.5 Distribution of staging for colorectal cancer.

Liver 112
100 120
Lung/Pleura 57
60 80
Peritoneum 33
40
Distant L.N. 13

Bone 8

Other 7

Brain 4

0 20

Figure 5.6 Distribution of metastasis for colorectal cancer.

45

CANCER REPORT 2021

LUNG AND BRONCHUS

Table 5.5 Age and gender of lung cancer. 66.2 (11.2)
67.0 (27:91)
Special Notes
Age 0.0%
Mean and standard deviation age at diagnosis (years)
213 (49.5%)
Median and range age at diagnosis 217 (50.5%)
% of the patient is lower than 15 year of age at diagnosis
Gender 0.98:1
Male
Total
Female N%
Sex ratio (male: female) 5 1.2
425 98.8
Table 5.6 Most valid method of diagnosis for lung cancer. 430 100.0

Basis of diagnosis Male % Female
Clinical investigation/imaging N 0.9 N%
2 3 1.4
214 98.6
Histology of primary 211 99.1 217 100.0

Total 213 100.0

80

70

60

50

40

30

20

10

0
20+ 30+ 40+ 50+ 60+ 70+ 80+

Male 0 3 14 30 75 63 28

Female 1 6 10 48 76 49 27

Figure 5.7 Age at diagnosis of lung cancer, 2021, by sex.

46

CANCER REPORT 2021

Unknown. 7.4% Stage I. 11.9%
Stage II. 4.4%

Stage III. 15.3%

Stage IV. 60.9%

Figure 5.8 Distribution of staging for lung cancer.

Lung/Pleura 142

Brain 70

Bone 75

Liver 39

Distant L.N. 28

Other 26

Peritoneum 8

Skin 1

Unknown 1

0 20 40 60 80 100 120 140 160

Figure 5.9 Distribution of metastasis for lung cancer.

47

CANCER REPORT 2021

LIVER AND INTRAHEPATIC BILE DUCTS

Table 5.7 Age and gender of liver and bile duct cancer. 64.1 (14.1)
65.0 (0:102)
Special Notes
Age 1.2%
Mean and standard deviation age at diagnosis (years)
219 (69.8%)
Median and range age at diagnosis 95 (30.3%)
2.3:1
% of the patient is lower than 15 year of age at diagnosis
Total
Gender N%
Male 5 1.2
Female 425 98.8
Sex ratio (male: female) 430 100.0

Table 5.8 Most valid method of diagnosis for liver and bile duct cancer.

Basis of diagnosis Male % Female
N 0.9 N%
Clinical investigation/imaging 2 99.1 3 1.4
Histology of primary 211 100.0 214 98.6
Total 213 217 100.0

90 0+ 20+ 30+ 40+ 50+ 60+ 70+ 80+
80 3 3 4 19 49 77 45 19
70 1 0 0 2 17 32 24 19
60
50
40
30
20
10
0

Male
Female

Figure 5.10 Age at diagnosis of liver and bile duct cancer, 2021 by sex.

48

CANCER REPORT 2021

Stage II, 0.6% Stage III, 3.2%

Stage IV, 22.0%

Unknown, 74.2%

Figure 5.11 Distribution of staging for liver and bile duct cancer.

Lung/Pleura 29
30
Peritoneum 22

Liver 21

Bone 15

Distant L.N. 12

Other 1

0 5 10 15 20 25

Figure 5.12 Distribution of metastasis for liver and bile duct cancer.

49

CANCER REPORT 2021

PROSTATE GLAND

Table 5.9 Age and gender of prostate gland cancer. 69.6 (8.1)
69.0 (46:94)
Special Notes
Age 0.0%
Mean and standard deviation age at diagnosis (years)
294 (100.0%)
Median and range age at diagnosis

% of the patient is lower than 15 year of age at diagnosis
Gender
Male

Table 5.10 Most valid method of diagnosis for prostate gland cancer.

Basis of diagnosis Male % Female Total
N 100.0 N% N%
Histology of primary 260 100.0 0 0.0 260 100.0
Total 260 0 0.0 260 100.0

140

120

100

80

60

40

20

0 70+ 80+
40+ 50+ 60+ 103 37

Male 1 28 125

Figure 5.13 Age at diagnosis of prostate gland cancer, 2021 by sex.

50

CANCER REPORT 2021

Stage I, 3.4% Stage II, 3.1%

Stage III, 7.8%
Stage IV, 19.4%

Unknown, 66.3%

Figure 5.14 Distribution of staging for prostate gland cancer.

Bone 47

Lung/Pleura 10

Distant L.N. 8

Liver 3

Brain 1

0 5 10 15 20 25 30 35 40 45 50

Figure 5.15 Distribution of metastasis for prostate gland cancer.

51

CANCER REPORT 2021

THYROID GLAND

Table 5.11 Age and gender of thyroid gland cancer. 50.2 (15.1)
51.0 (11:83)
Special Notes
Age 0.7%
Mean and standard deviation age at diagnosis (years)
46 (17.1%)
Median and range age at diagnosis 223 (82.9%)
% of the patient is lower than 15 year of age at diagnosis
Gender 0.2:1
Male
Female Total
Sex ratio (male: female) N%
269 100.0
Table 5.12 Most valid method of diagnosis for thyroid gland cancer. 269 100.0

Basis of diagnosis Male % Female
N 100.0 N%
Histology of primary 46 100.0 223 100.0
Total 46 223 100.0

60

50

40

30

20

10

0
10+ 20+ 30+ 40+ 50+ 60+ 70+ 80+

Male 1 1 6 12 7 12 7 0

Female 3 20 40 46 49 45 19 1

Figure 5.16 Age at diagnosis of thyroid gland cancer, 2021, by sex.

52

CANCER REPORT 2021

Unknown, 19.0%

Stage III, 0.7% Stage IV, 4.1%

Stage II,4.8% Stage I, 71.4%

Figure 5.17 Distribution of staging for thyroid gland cancer.

Distant L.N. 5

Bone 4

Lung/Pleura 4

Other 1

0123456

Figure 5.18 Distribution of metastasis for thyroid gland cancer.

53

CANCER REPORT 2021

CHILDHOOD CANCER

Table 5.13 Age and gender of childhood cancer. 5.7 (4.4)
5.0 (0:14)
Special Notes 100.0%
Age
46 (56.1%)
Mean and standard deviation age at diagnosis (years) 36 (43.9%)

Median and range age at diagnosis 1.27:1

% of the patient is lower than 15 year of age at diagnosis Total
N%
Gender 1 1.2
Male 81 98.8
Female 82 100.0
Sex ratio (male: female)

Table 5.14 Most valid method of diagnosis for childhood cancer.

Basis of diagnosis Male Female %
N% N 0.0
Clinical investigation/imaging 1 2.2 0 100.0
Histology of primary 45 97.8 36 100.0
Total 45 100.0 36

Leukemias-I 10 9 9
62
Brain/CNS-III 5 0-4
1 5-9
Retinoblastoma-V 9 10-14
10
Soft-tissue-IX 3 12 20 30

Malignant bone-VIII 4 2

Sympathetics NER.-IV 5

Lymphomas-II 1 3

Hepatic-VII 4

Carcinomas-XI 1 3

Germ cell-X 1

Renal-VI 1

0

Figure 5.19 Number of childhood cancer by ICCC group, age<15, both sexes.

54

CANCER REPORT 2021

Table 5.15 Number of cancer in childhood by ICCC group, age <15 both sexes.

ICCC GROUP Male Female M:F %MV

Leukemia - I ≤4 5-9 10-14 Total ≤ 4 5-9 10-14 Total
Lymphoma - II
Brain/CNS - III 5 7 6 18 5 2 3 10 1.8 100.0
Sympathetics NER. - IV
Retinoblastoma - V 13 0 4 00 0 0 0.0 100.0
Renal - VI
Hepatic - VII 22 1 5 34 1 8 0.6 100.0
Malignant bone - VIII
Soft Tissue - IX 30 0 3 20 0 2 1.5 100.0
Germ Cell - X
Carcinomas - XI 60 0 6 31 0 4 1.5 100.0
10 0 1 00 0 0 0.0 100.0
Total
30 0 3 10 0 1 3.0 75.0

01 1 2 03 1 4 0.5 100.0

21 1 4 10 1 2 2.0 100.0

00 0 0 10 0 1 0.0 100.0

00 0 0 01 3 4 0.0 100.0

23 14 9 46 16 11 9 36 1.3 98.8

25

20 Male
Female

15

10

5

0

Figure 5.20 Number of cases of all childhood cancer by ICCC and Age Group, both Sexes.
55

CANCER REPORT 2021

CHAPTER VI
DISTRIBUTION BY REGIONAL OF THAILAND

Table 6.1 Number of cancer cases by region, 2021.

Bangkok Region Number %
Central Total
East 1,880 44.7
North-east 1,470 34.9
West 308 7.3
South 190 4.5
North 175 4.2
151 3.6
0.8
33 100.0
4,207

Bangkok 44.7%

Central 34.9%

East 7.3%

North-east 4.5%

West 4.2%

South 3.6%

North 0.8%

Figure 6.1 Distribution of region, 2021. (%)

56

CANCER REPORT 2021

Table 6.2 Number of cancer cases by topography and region, 2021.

Topography Bangkok Central East Northeast West South North Total

C00 Lip 1 00 1 00 0 2
C01 Base of Tongue 6
C02 Other and unspecified part of Tongue 2 31 0 00 0 23
C03 Gum 8
C04 Floor of Mouth 11 72 3 00 0 4
C05 Palate 9
C06 Other and unspecified part of Mouth 3 11 2 10 0 6
C07 Parotid gland 9
C08 Other and unspecified major salivary 2 20 0 00 0
glands
C09 Tonsil 3 32 1 00 0
C10 Oropharynx
C11 Nasopharynx 2 11 0 11 0
C12 Pyriform sinus
C13 Hypopharynx 4 31 0 10 0

C14 Pharynx 1 2 0 0 11 1 6

C15 Esophagus 4 2 2 0 01 0 9
C16 Stomach 2 1 0 0 00 0 3
17 15 2 4 2 3 2 45
C17 Small Intestine 1 4 1 1 00 0 7
3 3 0 0 00 0 6
C18-C20 Colorectal
C21 Anus and Anal canal 1 0 0 0 00 0 1
C22 Liver and Intrahepatic bile ducts
16 11 5 1 1 1 0 35
C23 Gallbladder 36 35 9 4 4 2 0 90
C24 Other and unspecified parts of biliary 6 2 1 0 00 0 9
tract 226 149 31 16 20 9 3 454
C25 Pancreas 2 2 0 0 00 0 4
C30 Nasal Cavity 117 125 32 15 13 7 5 314
C31 Accessory sinuses 5 1 1 1 00 0 8
C32 Larynx
C34 Bronchus and Lung 8 9 3 1 0 1 0 22
C37 Thymus
30 27 3 2 2 1 0 65
C38 Heart, Mediastinum
C40 Bones, Joints and articular cartilage of 4 2 2 1 1 1 0 11
limbs
C41 Bones, Joints and articular cartilage of 2 3 1 0 10 0 7
other and unspecified sites
15 32 0 2 1 0 23

192 161 26 14 18 15 4 430

8 2 0 2 0 0 0 12

9 1 0 1 1 0 0 12

2 3 0 0 00 0 5

2 1 2 2 10 0 8

57

CANCER REPORT 2021

Topography Bangkok Central East Northeast West South North Total

C42 Hematopoietic and Reticuloendothelial 96 83 9 16 94 5 222
systems
C44 Skin 79 62 12 4 77 3 174
C47 Peripheral nerves and autonomic nervous
system 1 00 0 00 0 1
C48 Retroperitoneum and Peritoneum
C49 Connective, Subcutaneous and Other soft 3 31 0 01 0 8
tissues
C50 Breast 20 17 2 1 25 0 47

C51 Vulva 342 231 47 28 25 22 1 696
4
C52 Vagina 2 20 0 00 0 3
C53 Cervix uteri 89
C54 Corpus uteri 3 00 0 00 0 124
C55 Uterus 3
C56 Ovary 42 26 7 5 44 1 73
C57 Other and Unspecified female genital
organs 61 38 5 5 77 1 2
C58 Placenta
C60 Penis 0 20 1 00 0 1
C61 Prostate gland 7
C62 Testis 31 24 3 9 33 0 294
C64 Kidney 11
C65 Renal pelvis 2 00 0 00 0 102
C66 Ureter 7
C67 Bladder 1 00 0 00 0 13
C68 Other and Unspecified urinary organs 95
C69 Eye and Adnexa 2 41 0 00 0 1
C71 Brain 26
C72 Spinal cord 147 102 22 7 10 6 0 40
C73 Thyroid gland 4
C74 Adrenal gland 3 80 0 00 0 269
C75 Other endocrine glands 8
C76 Other and ill-defined sites 41 35 10 1 68 1 5
C77 Lymph nodes 4
C80 Unknown primary site 1 12 2 01 0 204
17
Total 5 31 4 00 0 4,207

46 23 10 4 48 0

0 10 0 00 0

5 74 7 10 2

13 16 4 3 22 0

1 11 0 10 0

102 104 13 14 14 19 3

3 40 0 10 0

1 30 0 00 1

1 10 1 10 0

78 79 23 6 8 10 0

11 60 0 00 0

1,880 1,470 308 190 175 151 33

58

CANCER REPORT 2021

Table 6.3 Distribution of topography in Bangkok, 2021. Number %
1 0.1
Topography 2 0.1
C00 Lip 11 0.6
C01 Base of Tongue 3 0.2
C02 Other and unspecified part of Tongue 2 0.1
C03 Gum 3 0.2
C04 Floor of Mouth 2 0.1
C05 Palate 4 0.2
C06 Other and unspecified part of Mouth 1 0.1
C07 Parotid gland 4 0.2
C08 Other and unspecified major salivary glands 2 0.1
C09 Tonsil 17 0.9
C10 Oropharynx 1 0.1
C11 Nasopharynx 3 0.2
C12 Pyriform sinus 1 0.1
C13 Hypopharynx 16 0.9
C14 Pharynx 36 1.9
C15 Esophagus 6 0.3
C16 Stomach 12.0
C17 Small Intestine 226 0.1
C18-C20 Colorectal 2 6.2
C21 Anus and Anal canal
C22 Liver and Intrahepatic bile ducts 117 0.3

C23 Gallbladder 5 0.4
1.6
C24 Other and unspecified parts of biliary tract 8 0.2
C25 Pancreas 30 0.1
C30 Nasal Cavity 4 0.8
C31 Accessory sinuses 2 10.2
C32 Larynx 15 0.4
C34 Bronchus and Lung 192
C37 Thymus 8 0.5

C38 Heart, Mediastinum 9 0.1

C40 Bones, Joints and articular cartilage of limbs 2 0.1

C41 Bones, Joints and articular cartilage of other and unspecified sites 2 5.1
4.2
C42 Hematopoietic and Reticuloendothelial systems 96
C44 Skin 79 0.1

C47 Peripheral nerves and autonomic nervous system 1 0.2
1.1
C48 Retroperitoneum and Peritoneum 3 18.2
C49 Connective, Subcutaneous and Other soft tissues 20 0.1
C50 Breast 342 0.2
C51 Vulva 2 2.2
C52 Vagina 3
C53 Cervix uteri 42

59

CANCER REPORT 2021 Number %

Topography 61 3.2
C54 Corpus uteri 31 1.7
C56 Ovary 2 0.1
C57 Other and Unspecified female genital organs 1 0.1
C58 Placenta 2 0.1
C60 Penis 147 7.8
C61 Prostate gland 3 0.2
C62 Testis 41 2.2
C64 Kidney 1 0.1
C65 Renal pelvis 5 0.3
C66 Ureter 46 2.5
C67 Bladder 5 0.3
C69 Eye and Adnexa 13 0.7
C71 Brain 1 0.1
C72 Spinal cord 102 5.4
C73 Thyroid gland 3 0.2
C74 Adrenal gland 1 0.1
C75 Other endocrine glands 1 0.1
C76 Other and ill-defined sites 78 4.2
C77 Lymph nodes 11 0.6
C80 Unknown primary site 1,880 100.0

Total

C50 342
C18-C20
Topography 226
C34 192
C61 147
C22 117
C73 102
C42 96
C44 79
C77 78
C54 61
Number of Patients

Figure 6.2 Leading cancer in Bangkok, 2021.

60

CANCER REPORT 2021

Table 6.4 Distribution of topography in Central, 2021. Number %
3 0.2
Topography 7 0.5
C01 Base of Tongue 1 0.1
C02 Other and unspecified part of Tongue 2 0.1
C03 Gum 3 0.2
C04 Floor of Mouth 1 0.1
C05 Palate 3 0.2
C06 Other and unspecified part of Mouth 2 0.1
C07 Parotid gland 2 0.1
C08 Other and unspecified major salivary glands 1 0.1
C09 Tonsil 15 1.0
C10 Oropharynx 4 0.3
C11 Nasopharynx 3 0.2
C12 Pyriform sinus 11 0.8
C13 Hypopharynx 35 2.4
C15 Esophagus 2 0.1
C16 Stomach 10.1
C17 Small Intestine 149 0.1
C18-C20 Colorectal 2 8.5
C21 Anus and Anal canal 0.1
C22 Liver and Intrahepatic bile ducts 125 0.6
C23 Gallbladder 1
C24 Other and unspecified parts of biliary tract 9 1.8
C25 Pancreas
C30 Nasal Cavity 27 0.1
C31 Accessory sinuses 0.2
C32 Larynx 2 0.2
C34 Bronchus and Lung 3 11.0
C37 Thymus 3 0.1
C38 Heart, Mediastinum 161 0.1
C40 Bones, Joints and articular cartilage of limbs 2 0.2
C41 Bones, Joints and articular cartilage of other and unspecified sites 1
3 0.1
C42 Hematopoietic and Reticuloendothelial systems
1 5.7
C44 Skin
C48 Retroperitoneum and Peritoneum 83 4.2
C49 Connective, Subcutaneous and Other soft tissues
C50 Breast 62 0.2
1.2
C51 Vulva 3
C53 Cervix uteri 17 15.7
C54 Corpus uteri
231 0.1
1.8
2 2.6
26
38

61

CANCER REPORT 2021 Number %

Topography 2 0.1
C55 Uterus 24 1.6
C56 Ovary 4 0.3
C60 Penis 102 6.9
C61 Prostate gland 8 0.5
C62 Testis 35 2.4
C64 Kidney 1 0.1
C65 Renal pelvis 3 0.2
C66 Ureter 23 1.6
C67 Bladder 1 0.1
C68 Other and Unspecified urinary organs 7 0.5
C69 Eye and Adnexa 16 1.1
C71 Brain 1 0.1
C72 Spinal cord 104 7.1
C73 Thyroid gland 4 0.3
C74 Adrenal gland 3 0.2
C75 Other endocrine glands 1 0.1
C76 Other and ill-defined sites 79 5.4
C77 Lymph nodes 6 0.4
C80 Unknown primary site 1,470 100.0

Total

C50 231
C34
Topography C18-C20 161
C22 149
C73 125
C61 104
C42 102
C77 83
C44 79
C54 62
38
Number of Patients

Figure 6.3 Leading cancer in Central, 2021.
62

CANCER REPORT 2021

Table 6.5 Distribution of topography in East, 2021. Number %
1 0.3
Topography 2 0.7
C01 Base of Tongue 1 0.3
C02 Other and unspecified part of Tongue 2 0.7
C03 Gum 1 0.3
C05 Palate 1 0.3
C06 Other and unspecified part of Mouth 2 0.7
C07 Parotid gland 2 0.7
C09 Tonsil 1 0.3
C11 Nasopharynx 5 1.6
C12 Pyriform sinus 9 2.9
C15 Esophagus 1 0.3
C16 Stomach 31 10.1
C17 Small Intestine 32 10.4
C18-C20 Colorectal 1 0.3
C22 Liver and Intrahepatic bile ducts 3 1.0
C23 Gallbladder 3 1.0
C24 Other and unspecified parts of biliary tract 2 0.7
C25 Pancreas 1 0.3
C30 Nasal Cavity 2 0.7
C31 Accessory sinuses 26 8.4
C32 Larynx 2 0.7
C34 Bronchus and Lung
C41 Bones, Joints and articular cartilage of other and unspecified sites 9 2.9
C42 Hematopoietic and Reticuloendothelial systems 12 3.9
C44 Skin 1 0.3
C48 Retroperitoneum and Peritoneum 2 0.7
C49 Connective, Subcutaneous and Other soft tissues 47 15.3
C50 Breast 7 2.3
C53 Cervix uteri 5 1.6
C54 Corpus uteri
C56 Ovary 3 1.0

C60 Penis 1 0.3

C61 Prostate gland 22 7.1
C64 Kidney 10 3.3
C65 Renal pelvis 2 0.7

63

CANCER REPORT 2021 Topography Number %
Total
C66 Ureter 1 0.3
C67 Bladder
C69 Eye and Adnexa 10 3.3
C71 Brain 4 1.3
C72 Spinal cord 4 1.3
C73 Thyroid gland 1 0.3
C77 Lymph nodes 13 4.2
23 7.5
308 100.0

C50 47
C22
C18-C20 32
C34 31
C77
Topography C61 26
C73 23
C44 22
C67
C64 13
12
10
10

Number of Patients

Figure 6.4 Leading cancer in East, 2021.

64

CANCER REPORT 2021

Table 6.6 Distribution of topography in North-East, 2021. Number %
1 0.5
Topography 3 1.6
C00 Lip 2 1.1
C02 Other and unspecified part of Tongue 1 0.5
C03 Gum 4 2.1
C05 Palate 1 0.5
C11 Nasopharynx 1 0.5
C12 Pyriform sinus 4 2.1
C15 Esophagus 16 8.4
C16 Stomach 15 7.9
C18-C20 Colorectal 1 0.5
C22 Liver and Intrahepatic bile ducts 1 0.5
C23 Gallbladder 2 1.1
C24 Other and unspecified parts of biliary tract 1 0.5
C25 Pancreas 14 7.4
C30 Nasal Cavity 2 1.1
C34 Bronchus and Lung 1 0.5
C37 Thymus 2 1.1
C38 Heart, Mediastinum 16 8.4
C41 Bones, Joints and articular cartilage of other and unspecified sites 4 2.1
C42 Hematopoietic and Reticuloendothelial systems 1 0.5
C44 Skin 28 14.7
C49 Connective, Subcutaneous and Other soft tissues 5 2.6
C50 Breast 5 2.6
C53 Cervix uteri 1 0.5
C54 Corpus uteri 9 4.7
C55 Uterus 7 3.7
C56 Ovary 1 0.5
C61 Prostate gland 2 1.1
C64 Kidney 4 2.1
C65 Renal pelvis
C66 Ureter

65

CANCER REPORT 2021

C67 Bladder Topography Number %
C69 Eye and Adnexa Total 4 2.1
C71 Brain
C73 Thyroid gland 7 3.7
C76 Other and ill-defined sites
C77 Lymph nodes 3 1.6
14 7.4

1 0.5

6 3.2
190 100.0

C50 28

C42 16

C18-C20 16

C22 15

Topography C73 14

C34 14

C56 9

C69 7

C61 7

C77 6
Number of Patients

Figure 6.5 Leading cancer in North-East, 2021.

66

CANCER REPORT 2021

Table 6.7 Distribution of topography in West, 2021. Number %
1 0.6
Topography 1 0.6
C03 Gum 1 0.6
C06 Other and unspecified part of Mouth 1 0.6
C07 Parotid gland 2 1.1
C08 Other and unspecified major salivary glands 1 0.6
C11 Nasopharynx 4 2.3
C15 Esophagus 20 11.4
C16 Stomach 13 7.4
C18-C20 Colorectal 2 1.1
C22 Liver and Intrahepatic bile ducts 1 0.6
C25 Pancreas 1 0.6
C30 Nasal Cavity 2 1.1
C31 Accessory sinuses 18 10.3
C32 Larynx 1 0.6
C34 Bronchus and Lung 1 0.6
C38 Heart, Mediastinum 9 5.1
C41 Bones, Joints and articular cartilage of other and unspecified sites 7 4.0
C42 Hematopoietic and Reticuloendothelial systems 2 1.1
C44 Skin 25 14.3
C49 Connective, Subcutaneous and Other soft tissues 4 2.3
C50 Breast 7 4.0
C53 Cervix uteri 3 1.7
C54 Corpus uteri 10 5.7
C56 Ovary 6 3.4
C61 Prostate gland 4 2.3
C64 Kidney 1 0.6
C67 Bladder 2 1.1
C69 Eye and Adnexa 1 0.6
C71 Brain 14 8.0
C72 Spinal cord 1 0.6
C73 Thyroid gland
C74 Adrenal gland

67

CANCER REPORT 2021

C76 Other and ill-defined sites Topography Number %
C77 Lymph nodes Total 1 0.6
8 4.6
C50 175 100.0

25

C18-C20 20

C34 18

C73 14

Topography C22 13

C61 10

C42 9

C77 8

C54 7

C44 7
Number of Patients

Figure 6.6 Leading cancer in West, 2021.

68

CANCER REPORT 2021

Table 6.8 Distribution of topography in South, 2021. Number %
1 0.7
Topography 1 0.7
C06 Other and unspecified part of Mouth 1 0.7
C08 Other and unspecified major salivary glands 3 2.0
C09 Tonsil 1 0.7
C11 Nasopharynx 2 1.3
C15 Esophagus 9 6.0
C16 Stomach 7 4.6
C18-C20 Colorectal 1 0.7
C22 Liver and Intrahepatic bile ducts 1 0.7
C24 Other and unspecified parts of biliary tract 1 0.7
C25 Pancreas 1 0.7
C30 Nasal Cavity 15 9.9
C32 Larynx 4 2.7
C34 Bronchus and Lung 7 4.6
C42 Hematopoietic and Reticuloendothelial systems 1 0.7
C44 Skin 5 3.3
C48 Retroperitoneum and Peritoneum 22 14.6
C49 Connective, Subcutaneous and Other soft tissues 4 2.7
C50 Breast 7 4.6
C53 Cervix uteri 3 2.0
C54 Corpus uteri 6 4.0
C56 Ovary 8 5.3
C61 Prostate gland 1 0.7
C64 Kidney 8 5.3
C65 Renal pelvis 2 1.3
C67 Bladder
C71 Brain

69

CANCER REPORT 2021 Topography Number %
Total 19 12.6
C73 Thyroid gland 10 6.6
C77 Lymph nodes 151 100.0

C50 22
C73 19
C34
Topography C77 15
C18-C20 10
C67 9
C64 8
C54 8
C44 7
C22 7
7
Number of Patients

Figure 6.7 Leading cancer in South, 2021.

70

CANCER REPORT 2021

Table 6.9 Distribution of topography in North, 2021. Number %

Topography 1 3.0
C08 Other and unspecified major salivary glands 2 6.1
C11 Nasopharynx 3 9.1
C18-C20 Colorectal 5 15.2
C22 Liver and Intrahepatic bile ducts 4 12.1
C34 Bronchus and Lung 5 15.2
C42 Hematopoietic and Reticuloendothelial systems 3 9.1
C44 Skin 1 3.0
C50 Breast 1 3.0
C53 Cervix uteri
C54 Corpus uteri 1 3.0
C64 Kidney 1 3.0
C69 Eye and Adnexa 2 6.1
C73 Thyroid gland 3 9.1
C75 Other endocrine glands 1 3.0

Total 33 100.0

C42 5
C22 5
C34
C73 4
C44
Topography C18-C20 3
C69 3
C11 3
C75 2
C64 2
1
1
Number of Patients

Figure 6.8 Leading cancer in North, 2021.

71

CANCER REPORT 2021

Table 6.10 Distribution of staging for breast cancer of region, 2021.

Staging

Region Stage 0 Stage I Stage II Stage III Stage IV Unknown
34 87 112 44 36 29
Bangkok 14 61 85 34 15 22
Central 6 13 15 6 5 2
East 2 4 10 4 4 4
Northeast 3 4 11 4 3 0
West 1 9 6 1 2 3
South 0 1 0 0
North 00

120

100

80
Stage 0

Stage I
60

Stage II

Stage III
40

Stage IV

Unknown
20

0 Central East Northeast West South North
Bangkok

Figure 6.9 Distribution of staging for breast cancer of region, 2021.

72

CANCER REPORT 2021

Table 6.11 Distribution of staging for colorectal cancer of region, 2021.

Region Stage I Stage II Staging Stage IV Unknown
17 47 Stage III 75 20
Bangkok 5 41 46 14
Central 2 6 67 10 1
East 2 3 43 10 1
West 1 3 12 6 0
Northeast 0 3 4 3 0
South 0 0 6 1 1
North 3
1

80 Stage I
70 Stage II
60 Stage III
50 Stage IV
40 Unknown
30
20 Central East West Northeast South North
10
0

Bangkok

Figure 6.10 Distribution of staging for colorectal cancer of region, 2021.

73

CANCER REPORT 2021

Table 6.12 Distribution of staging for lung cancer of region, 2021.

Region Stage I Stage II Staging Stage IV Unknown
25 9 Stage III 124 14
Bangkok 21 7 90 12
Central 3 1 20 15 2
East 0 2 31 14 0
West 1 0 5 8 2
South 1 0 2 8 0
Northeast 0 0 3 3 0
North 4
1

140

120

100 Stage I
Stage II
80 Stage III
Stage IV
60 Unknown

40

20

0 Central East West South Northeast North
Bangkok

Figure 6.11 Distribution of staging for lung cancer of region, 2021.

74

Table 6.13 Distribution of staging for liver cancer of region, 2021. CANCER REPORT 2021

Region Stage II Stage III Staging Unknown
1 3 Stage IV 95
Central 0 4 26 83
Bangkok 0 0 30 24
East 0 3 8 10
Northeast 1 0 2 11
West 0 0 1 6
South 0 0 1 4
North 1

100

90

80 Stage II
Stage III
70 Stage IV
Unknown
60

50

40

30

20

10

0 Bangkok East Northeast West South North
Central

Figure 6.12 Distribution of staging for liver cancer of region, 2021.

75

CANCER REPORT 2021

Table 6.14 Distribution of staging for prostate cancer of region, 2021.

Region Stage I Stage II Staging Stage IV Unknown
3 5 Stage III 32 94
Bangkok 6 3 19 66
Central 1 0 13 5 15
East 0 1 8 1 8
West 0 0 1 0 7
Northeast 0 0 0 0 5
South 0
1

100 Stage I
90 Stage II
80 Stage III
70 Stage IV
60 Unknown
50
40 Central East West Northeast South
30
20
10
0
Bangkok

Figure 6.13 Distribution of staging for prostate cancer of region, 2021.

76

CANCER REPORT 2021

CHAPTER VII
FIVE YEAR OVERALL SURVIVAL OF PATIENTS AT RAMATHIBODI

% Survival Probability 92 94

100

90 82 84

80 77 76 79
73

70 67
58
60 56 55 61
54

50

40 34

30 28 29 29
23
23

20

10

-

diagnosed 2011-2015 diagnosed 2016-2020

Figure 7.1 Five year overall survival of patients at Ramathibodi.

* Follow up till March 2022

77

Title Ramathibodi Cancer Report 2021

Editorial Board Assoc. Prof. Ekaphop Sirachainan
Chairman of Ramathibodi Comprehensive Cancer Center

Prof. Sarikapan Wilailak
Chairman of Ramathibodi Cancer Registry

Nintita Sripaiboonkij Thokanit, Dr.PH
Ramathibodi Comprehensive Cancer Center

Published by Ramathibodi Cancer Registry: A subsidiary of Ramathibodi
Comprehensive Cancer Center, Ramathibodi Hospital
270 Rama VI Road, Ratchatewi, Bangkok, Thailand 10400
Tel. & Fax. : +66 22010049, +66 22012682

Published 2022
Edition 1st edition
Physical 84 Pages
ISBN (e-book) 978-616-443-766-1

78